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The ovarian hormone 17β-estradiol is known to regulate the release, expression and 
immunoreactivity of arginine-vasopressin (AVP) in the supraoptic and paraventricular hypothalamic 
nuclei of rodents. Previous studies have shown that estrogen receptor α is involved in the effects of 
chronic estradiol administration on arginine-vasopressin immunoreactivity in the female rat 
hypothalamus. In this study we have examined the effect of an acute administration of estradiol or 
specific agonists for estrogen receptors α, β and G protein-coupled estrogen receptor 1 on the 
immunoreactivity of arginine-vasopressin in the hypothalamus of adult ovariectomized female rats. 
Acute estradiol administration resulted in a significant decrease in the number of arginine-
vasopressin immunoreactive neurons in the supraoptic and paraventricular nuclei after 24 hours. 
The effects of the specific estrogen receptors agonists suggest that the action of estradiol on 
arginine-vasopressin immunoreactivity is mediated in the supraoptic nucleus by G protein-coupled 
estrogen receptor 1 and in the paraventricular nucleus by both estrogen receptor β and G protein-
coupled estrogen receptor 1.  Thus, in contrast to previous studies on the effect of chronic 
estrogenic treatments, the present findings suggest that estrogen receptor β and G protein-coupled 
estrogen receptor 1 mediate the acute effects of estradiol on arginine-vasopressin immunoreactivity 
in the hypothalamus of ovariectomized rats. 
 





In addition to its role in reproduction, the ovarian hormone 17β-estradiol (E2) exerts numerous 
homeostatic actions, including the regulation of the levels of arginine-vasopressin (AVP) in plasma 
(Skowsky et al., 1979; Stone et al., 1989; Ho and Lee, 1992). Since the pioneering work of Sar and 
Stumpf (Sar and Stumpf, 1980 and Sar and Stumpf 1981), using autoradiographic analysis of [3H] 
E2 binding sites in the rodent brain, it is known that AVP neurons in the supraoptic (SON) and 
paraventricular (PVN) nuclei are direct targets of E2.  More recent studies have shown that SON 
and PVN neurons express estrogen receptors (ERs) (Alves et al., 1998; Suzuki and Handa, 2004; 
Suzuki and Handa, 2005; Grassi et al., 2017) and that E2 regulates AVP release, expression and 
immunoreactivity in SON and PVN (Greer et al., 1986; Liu et al., 1995; Swenson et al., 1998; 
Sladek et al., 2000; Nomura et al., 2002; Somponpun and Sladek, 2002; Almeida-Pereira et al., 
2016).  
 
In a previous study (Grassi et al., 2010), the role of ERα and ERβ in the regulation of AVP 
immunoreactivity in the SON and PVN was assessed after chronic E2 administration and we 
demonstrated that the observed changes in the AVP immunoreactivity in both nuclei are mediated 
by ERα and not by ERβ. However, the possible effects of acute changes in E2 levels on AVP 
immunoreactivity have not been yet determined.  In addition, recent findings indicate that the 
membrane associated G protein-coupled estrogen receptor 1 (GPER) is expressed in neurons of the 
SON and PVN (Grassi et al., 2017).  GPER may thus confer a previously unexplored additional 
level of complexity in the estrogenic regulation of AVP neurons in the SON and PVN. Therefore, in 
the present study we have examined the effects of the acute administration of specific agonists for 








2.1 Estrogenic regulation of AVP immunoreactivity in the SON 
Ovariectomized rats were injected with either vehicle (controls), 17β-estradiol (E2), the ERα 
agonist PPT, the ERβ agonist DPN or the GPER agonist G1. AVP immunoreactivity was assessed in 
the hypothalamus. Qualitative differences in AVP immunoreactivity in the SON were observed 
between the different experimental groups (Fig. 1). Animals injected with E2 showed a decreased 
immunostaining compared to controls (Fig. 1). No obvious differences in AVP immunostaining 
were detected between control animals and the animals injected with the ERα agonist PPT or the 
ERβ agonist DPN. In contrast, animals injected with the GPER agonist G1 showed a reduced AVP 
immunoreactivity compared to control animals (Fig. 1).   
 
The morphometric analysis of AVP immunoreactivity confirmed the qualitative observations. One-
way ANOVA showed a significant treatment effect (F4,17 = 9.32; P=0.0004). The post hoc 
Bonferroni’s test showed that the number of AVP positive cells was significantly decreased by the 
treatment with either E2 (P<0.01), or the selective GPER agonist G1 (P<0.01), compared to control 
animals (Fig. 2). In contrast, the ERα agonist PPT and the ERβ agonist DPN had no significant 
effects on the number of AVP immunoreactive cells (Fig. 2). 
 
2.2 Estrogenic regulation of AVP immunoreactivity in the PVN 
Qualitative differences in AVP immunoreactivity in the PVN were also observed between the 
different experimental groups (Fig. 3). Compared to controls, AVP immunoreactivity was decreased 
in the PVN of animals treated with E2, the ERβ agonist DPN or the GPER agonist G1 (Fig. 3). 
ANOVA analysis confirmed a significant treatment effect (F4,15=30.45; P<0.001). Post-hoc analysis 
revealed significant differences between the control and the E2 (P<0.001), DPN (P<0.001) and G1 




The PVN was subdivided in its four different sub-regions: the paraventricular dorsal cap (PaDC), 
the paraventricular lateral magnocellular subdivision (PaLM), the paraventricular medial 
magnocellular subdivision (PaMM) and the paraventricular parvocellular subdivision (PaV) (Fig. 
5).  ANOVA analysis revealed a treatment effect in the PaDC (F4,15=8.57; P<0.0008), PaLM 
(F4,15=27.73; P<0.0001) and PaMM (F4,16=4,56; P=0.0120). In contrast, no significant effect of 
treatment was detected in PaV (F4,15=2.74; P=0.0680) (Fig. 6). 
 
Compared to control values, the number of AVP immunopositive cells was significantly decreased 
in the PaDC by treatments with either E2 (P<0.05), the ERβ agonist DPN (P<0.05) or the GPER 
agonist G1 (P<0.05). Similar results were obtained in the PaLM, where the number of AVP 
immunoreactive cells was significantly decreased by E2 (P<0.001), DPN (P<0.001) and G1 
(P<0.001) (Fig. 6). In the PaMM, although estradiol treatment resulted in a significant (P<0.05) 
decrease in the number of AVP immunoreactive cells compared to control values, the effects of ER 
agonists did not reach statistical significance (Fig. 6).  
 
3. DISCUSSION 
The findings of the present study indicate that an acute administration of E2 to ovariectomized rats 
resulted in a significant decrease in the number of AVP immunoreactive neurons in the SON and 
PVN. This finding extends the results of previous studies showing that AVP neurons in the SON and 
PVN are regulated by E2. Thus, chronic E2 administration potentiates c-fos immunoreactivity in 
AVP neurons in the SON and/or PVN of ovariectomized rats submitted to water deprivation 
(Vilhena-Franco et al., 2016), hypovolemic shock (Mecawi et al., 2011) or hypertonic extracellular 
volume expansion (Vilhena-Franco et al., 2011). In addition, chronic E2 administration to 
ovariectomized rats increases AVP expression in the SON (Garcia et al., 2017) and AVP 




Surprisingly, the short-term effects of acute E2 administration observed in the present study, 
decreasing AVP immunoreactivity in the SON and the PVN, are opposite to the effects of chronic 
E2 treatment, which increases AVP immunoreactivity in these hypothalamic nuclei (Grassi et al., 
2010).  This different effect of chronic (Grassi et al., 2010) and acute (present study) estradiol 
treatments has been observed in female rats from the same strain that were ovariectomized at the 
same age (3 months) and the administration of estradiol was in both cases initiated seven days after 
ovariectomy. This suggests that acute and chronic actions of estradiol involve different mechanism 
to regulate AVP immunoreactivity in SON and PVN neurons.   
 
The physiological implications of the different regulation of AVP immunoreactivity in the 
hypothalamus by acute and chronic E2 treatments remain to be determined. E2 has vasodilator 
activity and low E2 levels after menopause represent a risk factor for the development of 
hypertension (Mendelsohn and Karas, 1999; Alecrin et al., 2004; Lima et al., 2005; Maas and 
Franke, 2009; Khalil, 2013). However, supraphysiological dosages of estrogens in first generation 
oral contraceptives were shown to increase blood pressure in young women (Oelkers, 1996) and 
chronic treatment with low doses of estradiol increased blood pressure in female rats (Subramanina 
et al., 2017). The effects of E2 in the control of blood pressure involve both ERα, ERβ and GPER 
(Traupe et al., 2007; Meyer et al., 2011) and are mediated by actions at different levels, including 
the regulation of AVP expression in magnocellular hypothalamic neurons (Pietranera et al., 2015).  
 
Differences in AVP immunoreactivity in magnocellular hypothalamic neurons induced by acute and 
chronic E2 treatments may potentially reflect changes in AVP synthesis and/or changes in AVP 
release, given that the hormone regulates both the expression and the release of AVP (Sladek et al., 
2000; Nomura et al., 2002; Somponpun and Sladek, 2002; Grassi et al., 2013; Pietranera et al., 
2015). It should be noted that, at least in some circumstances, increased AVP immunoreactivity in 
  
 8 
hypothalamic magnocellular neurons is associated with increased AVP release. For instance, this has 
been observed for the direct actions of angiotensin II in the brain, which participate in the 
upregulation of blood pressure and that are antagonized by E2 (Almeida-Pereira et al., 2016, 2018). 
Central angiotensin II administration increases AVP immunoreactivity in the PVN and in parallel 
increases AVP levels in plasma (Almeida-Pereira et al., 2016). Interestingly, subcutaneous injections 
of E2 block both effects of central angiotensin II administration (Almeida-Pereira et al., 2016). 
Thus, at least in this case, a decrease in AVP immunoreactivity induced by E2 in magnocellular 
neurons is associated with a decrease in AVP release. New experiments are needed to determine 
whether acute and chronic estradiol treatment have opposite effects in AVP expression and/or 
release. 
 
Our findings, using subtype selective ER agonists, suggest that the acute effect of E2 on AVP 
immunoreactivity in the hypothalamus of ovariectomized rats is mediated by GPER in the SON and 
by ERβ and GPER in the PVN.  This is in contrast with the effect of chronic E2 in AVP 
immunoreactivity in the SON and the PVN, which is mediated by ERα (Grassi et al., 2010). Since 
the acute effects of E2 are opposite to the effects of chronic E2 treatment, our present and previous 
findings indicate that the acute and chronic effects of E2 on AVP immunoreactivity in the 
hypothalamus of ovariectomized rats are mediated by different ER subtypes.  
 
Studies in cell lines have shown that ERα, ERβ and GPER have different effects on AVP 
transcription, being activated by ERα and inhibited by ERβ and GPER (Shapiro et al., 2000; Grassi 
et al., 2015; Grassi et al., 2013a). However, these differences cannot be directly translated to AVP 
regulation in the SON and the PVN in vivo, since in rats ERα is not expressed in AVP neurons in 
these hypothalamic nuclei (Shughrue et al., 1997; Merchenthaler et al., 2004; Suzuki and Handa, 
2005). In contrast, several studies have reported ERβ expression by AVP neurons in the SON and 
the PVN (Gruber et al., 1986; Alves et al., 1998; Suzuki and Handa, 2005). GPER 
  
 9 
immunoreactivity has been also detected in the rat SON and PVN (Brailoiu et al., 2007; Grassi et 
al., 2017) and GPER expression has been reported in AVP neurons in the SON and PVN of mice 
(Hazell et al., 2009).    
 
The absence of ERα expression in the SON and PVN of rats indicate that the ERα-mediated effects 
of E2 on AVP immunoreactivity in these hypothalamic nuclei could be indirect, involving other 
neuronal populations, while E2 may directly activate ERβ and GPER in the AVP neurons of the 
SON and PNV. The existence of parallel indirect and direct mechanism of action of E2 on SON and 
PVN AVP neurons may contribute to the different effects of each receptor subtype on AVP 
immunoreactivity. For instance, ERβ and GPER may exert a direct inhibitory effect on AVP 
transcription in SON and PVN neurons GPER (Shapiro et al., 2000; Grassi et al., 2013b; Grassi et 
al., 2015) while ERα could have a promoting effect through neuronal inputs arising from neurons 
expressing this ER subtype (Grassi et al., 2010). 
 
Another possible factor contributing to the differential involvement of each ER subtype in the 
effects of acute and chronic E2 treatments is the dissimilar consequences that these treatments may 
have on ER expression or ER signaling. Although this possibility has not been fully explored, it is 
known that chronic E2 treatment exerts a differential regulation of the expression of ERα and ERβ 
in different brain regions and neuronal populations (Osterlund et al., 1998; Prange-Kiel et al., 2003; 
Bohacek and Daniel, 2009). For instance, 17β-estradiol increases the expression of ERα, but 
decreases the expression of ERβ in hippocampal neurons in vitro (Patisaul et al., 1999). Chronic E2 
treatment also affects ER expression in the SON and the PVN (Patisaul et al., 1999; Suzuki and 
Harada, 2004). Patisaul et al. showed that chronic 17β-estradiol administration decreases the 
expression of ERβ in PVN neurons of ovariectomized rats (Patisaul et al., 1999). Furthermore, 
Suzuki and Harada treated ovariectomized rats with estradiol benzoate, for 3 days before they have 
been euthanized, and observed a significant decrease in the expression of ERβ in the SON and the 
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PVN (Suzuki and Harada, 2004). Therefore, it is plausible that chronic E2 treatment, by decreasing 
ERβ expression in the SON and PNV, could favor the up regulation of AVP immunoreactivity 
mediated by ERα. However, to our knowledge, there is no available information on the effects of E2 
treatments on the expression of ERα and GPER in the SON and the PVN.   
Further studies should determine the role of the expression of different ER subtypes in specific 
neuronal populations, the different transcriptional regulation of AVP by ERα, ERβ and GPER and 
the differential regulation of the expression of each ER form by chronic E2 on the regulation of 
AVP immunoreactivity in the SON and PVN. All these factors may together contribute to the 
different effects of acute and chronic E2 treatments on AVP regulation in these hypothalamic nuclei.  
 
In summary, in contrast to the previously observed ERα-dependent up regulation of the number of 
AVP immunoreactive cells in the SON and PVN by chronic estrogenic treatments, the present 
findings indicate that ERβ and GPER mediate acute effects of estradiol decreasing the AVP 
immunoreactivity in the hypothalamus of ovariectomized female rats. 
 
4. MATERIALS AND METHODS 
4.1 Animals and experimental treatments 
Wistar albino female rats from our in-house colony were kept on a 12:12-h light–dark cycle and 
received food and water ad libitum. Animals were handled in accordance with the guidelines 
published in the “NIH Guide for the care and use of laboratory animals”, the principles presented in 
the “Guidelines for the Use of Animals in Neuroscience Research” by the Society for Neuroscience, 
and following the European Union (2010/63/UE) and the Spanish legislation (L6/2013; 
RD53/2013). Experimental procedures were approved by our Institutional Animal Use and Care 
Committee (UNED, Madrid). Special care was taken to minimize animal suffering and to reduce the 




Female rats (n=20) were bilaterally ovariectomized at the age of 3 months under isoflurane 
anesthesia. They were then housed in plastic cages and randomly assigned to the different 
treatments. Seven days after surgery 4 rats per each group received one i.p. injection of either 
vehicle (corn oil), 17β-estradiol; BiogenCientifica, Madrid, Spain; (50μg/kg), the subtype-selective 
ERα agonist PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol; BiogenCientifica, Madrid, 
Spain; 1 mg/kg), the selective ERβ agonist DPN (2,3-bis(4-Hydroxyphenyl)-propionitrile; 
BiogenCientifica, Madrid, Spain; 1mg/kg), or the selective GPER agonist G-1 (((±)-1-
[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinolin-8-yl]-ethanone; BiogenCientifica, Madrid, Spain; 2,4 nmol/animal). Doses of 
the different ligands were based on a previous in vivo study [Waters et al., 2009; Santollo et al., 
2010; Grassi et al., 2013b; Grassi et al., 2013c; Dennis et al., 2009; Grassi et al., 2017]. 
Twenty-four hours after the injection of the estrogenic compounds all the animals were deeply 
anesthetized with pentobarbital (Normon Veterinary Division, Madrid, Spain, 50 mg/kg) and 
perfused through the left cardiac ventricle with 50 ml of saline solution (0.9% NaCl) followed by 
250 ml of fixative solution (4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4). Brains were 
quickly removed and immersed for 4–6 hours at 4ºC in the same fixative solution and then rinsed 
with phosphate buffer. Brains were placed for 72 hours in a 30% sucrose solution in PBS, frozen in 
liquid isopentane at −35ºC, and stored in a deep freezer at −80ºC until sectioning. Brains were 
serially cut in the coronal plane at 25 μm thickness with a cryostat, obtaining 4 series of adjacent 
serial sections. In each series, each section was 100 μm distant from the following one. The plane of 
sectioning was oriented to match the drawings corresponding to the transverse sections of the rat 
brain atlas of [Paxinos and Watson, 2013]. Sections were collected in multiwell plates with a 
cryoprotectant solution [Watson et al., 1986] and kept at -20°C.  
 
4.2 Immunohistochemistry 
The presence of AVP was detected by immunohistochemistry performed on free-floating sections 
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according to the following steps. Before the reaction, the sections collected in the cryoprotectant 
solution were washed overnight at 4ºC in PBS 0.1M, pH 7.3–7.4. The following day, free floating 
sections were first washed for 30 min at room temperature in PBS 0.1M, pH 7.3–7.4, containing 
0.2% Triton X-100 and 0.2% BSA. Sections were then treated for 10 min with a solution of PBS 
0.1M, pH 7.3–7.4, containing methanol/hydrogen peroxide (PBS/methanol 1:1 with 0.3% hydrogen 
peroxide) to quench endogenous peroxidase activity. Sections were washed for 30 min at room 
temperature in PBS 0.1M, pH 7.3–7.4, containing 0.2% Triton X-100 and 0.2% BSA and then 
incubated for 72 hours at 4°C with a rabbit polyclonal AVP antibody (Chemicon, Merck, Germany, 
reference AB1565) diluted 1:100,000 in 0.1M PBS, pH 7.3–7.4, containing 0.2% Triton X-100, 
0.2% BSA and 3% normal goat serum. A biotinylated goat anti-rabbit secondary antibody (Thermo 
scientific, Pierce, Rockford, IL, USA) was then used at a dilution of 1:300 for 120 min at room 
temperature. The antigen–antibody reaction was revealed by incubation with avidin-peroxidase 
complex (Thermo scientific, Pierce, Rockford, IL, USA) for 90 min. The peroxidase activity was 
visualized with a solution containing 0.187 mg/mL 3,3- diamino-benzidine (Sigma, Madrid, Spain) 
in PBS 0.1M, pH 7.3–7.4. The sections were washed in the PBS 0.1M, pH 7.3–7.4 and collected on 
chrome alum-gelatin coated slides, air dried, cleared in xylene, and cover slipped with DEPEX 
(VWR International Eurolab, Barcelona, Spain) for quantitative analysis. 
 
4.3 Morphometric analysis 
The quantitative analysis of AVP immunostaining was performed on coded sections without 
knowledge of the experimental group. Selected fields were acquired by a digital camera (Olympus 
DP25) connected to a Nikon eclipse E600 microscope using a x20 objective. The number of AVP 
positive cells was assessed in the SON and the PVN, using three coded sections per animal. Each 
section was 100 μm distant from the following one. Sections were positioned in the anteroposterior 
axis around bregma -1.3 mm for the SON and around bregma -1.8 mm for the PVN [Paxinos and 
Watson, 2013]. Data presented are the sum of the total number of immunolabeled cells in the three 
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sections for each rat. Because in previous studies we did not detect a lateralization of the 
distribution of AVP positive cells, counts were restricted to the right hemisphere of the 
hypothalamus. Given the anatomical heterogeneity of the PVN, a grid of 24 square boxes of 8 μm2 
each were used in each slice and the grid was precisely located ensuring the left side of the grid on 
the wall of the third ventricle. The grid overlaps the total area of the PVN. Cell counting was 
performed for each square box within the boundaries of the nucleus. The PVN subdivisions were 
identified following the detailed anatomical description provided for the rat by [Armstrong et al., 
1980] based on Nissl-stained material. The boxes corresponding to the same PVN subdivision, 
along the three coded sections, were grouped for the statistical analysis (see fig 5). In the SON, 
instead, all AVP positive cells within the anatomical boundaries of the nucleus were counted 
together. 
 
4.4 Statistical Analysis 
Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test, using the SPSS-
17.0 software (SPSS Inc, Chicago, USA). A value of P < 0.05 was considered statistically 
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Fig. 1, Representative examples of AVP immunoreactivity in the supraotic nucleus from 
ovariectomized rats treated with vehicle (Control), estradiol (E2), the ERα agonist PPT, the ERβ 
agonist DPN or the GPER agonist G1. *, Optic chiasm. Scale bar 100 μm. 
 
Fig. 2, Morphometric analysis of the number of AVP immunoreactive cells in the supraotic nucleus 
of ovariectomized rats treated with vehicle (control), estradiol (E2), the ERα agonist PPT, the ERβ 
agonist DPN or the GPER agonist G1. Data represents the mean±SEM. **, significant differences 
(P<0.01) versus the control group. 
 
Fig. 3, Representative examples of AVP immunoreactivity in the paraventricular nucleus from 
ovariectomized rats treated with vehicle (Control), estradiol (E2), the ERα agonist PPT, the ERβ 
agonist DPN or the GPER agonist G1. *, Third ventricle. Scale bar 100 μm. 
 
Fig. 4, Morphometric analysis of the number of AVP immunoreactive cells in the paraventricular 
nucleus of ovariectomized rats treated with vehicle (control), estradiol (E2), the ERα agonist PPT, 
the ERβ agonist DPN or the GPER agonist G1. Data represents the mean±SEM. ***, significant 
differences (P<0.001) versus the control group. ^^^, significant differences (P<0.001) versus the 
estradiol treated group. 
 
Fig. 5, Schematic representation of the anatomical subdivisions of the paraventricular nucleus: the 
paraventricular dorsal cap (PaDC), the paraventricular lateral magnocellular subdivision (PaLM), 
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the paraventricular medial magnocellular subdivision (PaMM) and the paraventricular parvocellular 
subdivision (PaV). Scale bar 100 μm. 
 
Fig. 6, Morphometric analysis of the number of AVP immunoreactive cells in the different 
subdivisions of the paraventricular nucleus of ovariectomized rats treated with vehicle (control), 
estradiol (E2), the ERα agonist PPT, the ERβ agonist DPN or the GPER agonist G1. Data represents 
the mean±SEM. Significant differences * p<0.05 and *** P<0.001 versus the control group. 






























Acute estradiol administration decrease the number of AVP immunoreactive neurons in SON and 
PVN 
ERβ and GPER mediate the acute effects of estradiol decreasing the AVP-ir in the PVN 
GPER mediates the acute effects of estradiol decreasing the AVP-ir in the SON 
 
 
 
